학술논문
The Impact of CoronaVac Vaccination on 28-day Mortality Rate of Critically Ill Patients with COVID-19 in Türkiye.
Document Type
Article
Author
Gül, Fethi; Kasapoğlu, Umut Sabri; Sabaz, Mehmet Süleyman; Ay, Pınar; Oktay, Burçin Doruk; Çalışkan, Gülbahar; Demir, Nalan; Sayan, İsmet; Kabadayı, Feyyaz; Altuntaş, Gülsüm; Gümüş, Ayça; Kırca, Hülya; Şanlı, Deniz; Acil, Fatma; Dedeoğlu, Andaç; Ural, Sedef Gülçin; Şen, İrem Akın; Aydın, Eda Macit; Dayanır, Hakan; Yelken, Birgül
Source
Subject
*RESEARCH
*HOSPITALS
*INTENSIVE care units
*HYPERTENSION
*COVID-19
*CONFIDENCE intervals
*COVID-19 vaccines
*CRITICALLY ill
*CROSS-sectional method
*AGE distribution
*PATIENTS
*APACHE (Disease classification system)
*VACCINE effectiveness
*DESCRIPTIVE statistics
*DEATH
*VACCINATION status
*SOCIODEMOGRAPHIC factors
*ODDS ratio
*LONGITUDINAL method
*COMORBIDITY
*EVALUATION
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
Language
ISSN
2146-3123
Abstract
Background: Vaccines against coronavirus disease-19 (COVID-19) have been effective in preventing symptomatic diseases, hospitalizations, and intensive care unit (ICU) admissions. However, data regarding the effectiveness of COVID-19 vaccines in reducing mortality among critically ill patients with COVID-19 remains unclear. Aims: To determine the vaccination status and investigate the impact of the COVID-19 vaccine on the 28-day mortality in critically ill patients with COVID-19. Study Design: Multicenter prospective observational clinical study. Methods: This study was conducted in 60 hospitals with ICUs managing critically ill patients with COVID-19. Patients aged ≥ 18 years with confirmed COVID-19 who were admitted to the ICU were included. The present study had two phases. The first phase was designed as a one-day point prevalence study, and demographic and clinical findings were evaluated. In the second phase, the 28-day mortality was evaluated. Results: As of August 11, 2021, 921 patients were enrolled in the study. The mean age of the patients was 65.42 ± 16.74 years, and 48.6% (n = 448) were female. Among the critically ill patients with COVID-19, 52.6% (n = 484) were unvaccinated, 7.7% (n = 71) were incompletely vaccinated, and 39.8% (n = 366) were fully vaccinated. A subgroup analysis of 817 patients who were unvaccinated (n = 484) or who had received two doses of the CoronaVac vaccine (n = 333) was performed. The 28-day mortality rate was 56.8% (n = 275) and 57.4% (n = 191) in the unvaccinated and two-dose CoronaVac groups, respectively. The 28-day mortality was associated with age, hypertension, the number of comorbidities, type of respiratory support, and APACHE II and sequential organ failure assessment scores (p < 0.05). The odds ratio for the 28-day mortality among those who had received two doses of CoronaVac was 0.591 (95% confidence interval: 0.413-0.848) (p = 0.004). Conclusion: Vaccination with at least two doses of CoronaVac within six months significantly decreased mortality in vaccinated patients than in unvaccinated patients. [ABSTRACT FROM AUTHOR]